263 related articles for article (PubMed ID: 22419715)
1. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
Tosi F; Negri C; Perrone F; Dorizzi R; Castello R; Bonora E; Moghetti P
J Clin Endocrinol Metab; 2012 May; 97(5):1712-9. PubMed ID: 22419715
[TBL] [Abstract][Full Text] [Related]
2. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
3. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
[TBL] [Abstract][Full Text] [Related]
4. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
5. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
6. Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
Sahin Y; Ayata D; Keleştimur F
Eur J Endocrinol; 1997 Apr; 136(4):410-5. PubMed ID: 9150702
[TBL] [Abstract][Full Text] [Related]
7. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
Nestler JE; Jakubowicz DJ
J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716
[TBL] [Abstract][Full Text] [Related]
8. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
9. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
11. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome.
McCartney CR; Bellows AB; Gingrich MB; Hu Y; Evans WS; Marshall JC; Veldhuis JD
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E902-8. PubMed ID: 14736706
[TBL] [Abstract][Full Text] [Related]
12. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist.
Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S
Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986
[TBL] [Abstract][Full Text] [Related]
13. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion.
Patel K; Coffler MS; Dahan MH; Yoo RY; Lawson MA; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2003 Nov; 88(11):5456-61. PubMed ID: 14602789
[TBL] [Abstract][Full Text] [Related]
14. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
15. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ovarian and adrenal sources of androgens in women with polycystic ovary syndrome. Dexamethasone and GnRH-agonist administration.
Fulghesu AM; Lanzone A; Fortini A; Guido M; Caruso A; Mancuso S
J Reprod Med; 1993 May; 38(5):387-92. PubMed ID: 8320677
[TBL] [Abstract][Full Text] [Related]
17. Variations of steroid hormone metabolites in serum and urine in polycystic ovary syndrome after nafarelin stimulation: evidence for an altered corticoid excretion.
Luppa P; Müller B; Jacob K; Kimmig R; Strowitzki T; Höss C; Weber MM; Engelhardt D; Lobo RA
J Clin Endocrinol Metab; 1995 Jan; 80(1):280-8. PubMed ID: 7829627
[TBL] [Abstract][Full Text] [Related]
18. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.
Sahin Y; Keleştimur F
Hum Reprod; 1997 May; 12(5):910-3. PubMed ID: 9194638
[TBL] [Abstract][Full Text] [Related]
19. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome.
Dunaif A; Graf M
J Clin Invest; 1989 Jan; 83(1):23-9. PubMed ID: 2642919
[TBL] [Abstract][Full Text] [Related]
20. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.
Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS
J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
